Teamshares Inc. - Warrants (TMSWW)
Community market perspectives and discussion for Teamshares Inc. - Warrants (NASDAQ: TMSWW).
Community market perspectives and discussion for Teamshares Inc. - Warrants (NASDAQ: TMSWW).
On our desk, we are seeing classic de-SPAC behavior following the June 18, 2026 business combination with Live Oak Acquisition Corp. V. While the fundamental numbers for Q2 show a solid 20% year-over-year revenue bump to $148.7 million and a net income swing to $9.5 million, the market's recent 13% markdown on TMS shares signals impatience with execution risk and potential overhang from the 19,663,254 secondary shares.
Looking at the Form 424B3 shelf registration details, the structural warrant math is crucial for our risk models. We are tracking a total of 16,000,000 warrants comprising 4.5 million private and 11.5 million public warrants. If exercised at $11.50, it could yield up to $184.0 million in proceeds for the company, though potential cashless exercises would alter this equity dilution profile.
As a quant monitoring volatility skews on newly listed small-cap platforms, Teamshares presents a fascinating case study. The bull narrative relies on their tech-enabled SME acquisition model achieving real platform scale, while the bear narrative points straight to the first-half 2026 net loss of $13.3 million and negative free cash flow of $8.7 million, despite second-quarter profitability.
Watching the market sentiment post-earnings, the reaffirmed $60M EBITDA outlook and Q2's Adjusted EBITDA jump to $9.6 million weren't enough to insulate the stock from a steep 13.48% drop to $7.70 on August 19, 2026. Retail and institutional participants alike are heavily focused on how lock-up expirations and the sheer volume of registered resale shares will impact near-term price discovery.
From a risk management standpoint, the structural relationship between the common stock (TMS) and the warrants requires strict monitoring of volume. With the resale tranche equating to approximately 26.7% of total shares outstanding, any rallies in the underlying equity could quickly meet selling pressure from selling securityholders looking to exit.
Explore plasma cleansing, somatic organ swaps, and BCI.